| Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors M Skribek, K Rounis, S Afshar, O Grundberg, S Friesland, G Tsakonas, ... European Journal of Cancer 145, 245-254, 2021 | 70 | 2021 |
| Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review T Konstantina, R Konstantinos, K Anastasios, M Anastasia, L Eleni, ... Lung cancer 135, 29-32, 2019 | 55 | 2019 |
| Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy MA Papadaki, AI Sotiriou, C Vasilopoulou, M Filika, D Aggouraki, ... Cancers 12 (6), 1556, 2020 | 35 | 2020 |
| Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective … K Rounis, D Makrakis, AP Tsigkas, A Georgiou, N Galanakis, C Papadaki, ... Translational Lung Cancer Research 10 (8), 3538, 2021 | 32 | 2021 |
| Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective … K Rounis, D Makrakis, C Papadaki, A Monastirioti, L Vamvakas, ... PloS one 16 (6), e0252537, 2021 | 23 | 2021 |
| Circulating MicroRNAs regulating DNA damage response and responsiveness to cisplatin in the prognosis of patients with non-small cell lung cancer treated with first-line … C Papadaki, A Monastirioti, K Rounis, D Makrakis, K Kalbakis, C Nikolaou, ... Cancers 12 (5), 1282, 2020 | 19 | 2020 |
| Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a ‘real-life’setting M Skribek, K Rounis, D Makrakis, S Agelaki, D Mavroudis, L De Petris, ... Cancers 12 (12), 3707, 2020 | 16 | 2020 |
| Complications following novel therapies for non‐small cell lung cancer M Skribek, K Rounis, G Tsakonas, S Ekman Journal of Internal Medicine 291 (6), 732-754, 2022 | 14 | 2022 |
| Correlation of clinical parameters with intracranial outcome in non-small cell lung cancer patients with brain metastases treated with Pd-1/Pd-L1 inhibitors as monotherapy K Rounis, M Skribek, D Makrakis, L De Petris, S Agelaki, S Ekman, ... Cancers 13 (7), 1562, 2021 | 12 | 2021 |
| Plasma-based microRNA expression analysis in advanced stage NSCLC patients treated with Nivolumab A Monastirioti, C Papadaki, D Kalapanida, K Rounis, K Michaelidou, ... Cancers 14 (19), 4739, 2022 | 10 | 2022 |
| A prognostic role for circulating microRNAs involved in macrophage polarization in advanced non-small cell lung cancer A Monastirioti, C Papadaki, K Rounis, D Kalapanida, D Mavroudis, ... Cells 10 (8), 1988, 2021 | 9 | 2021 |
| Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint … K Rounis, C Papadaki, D Makrakis, A Monastirioti, L Vamvakas, ... Annals of Oncology 30, ii61, 2019 | 9 | 2019 |
| Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune … S Agelaki, K Rounis, C Papadaki, AA Monastirioti, L Vamvakas, ... Journal of Clinical Oncology 37 (15_suppl), 9099-9099, 2019 | 6 | 2019 |
| MicroRNAs regulating tumor and immune cell interactions in the prediction of relapse in early stage breast cancer C Papadaki, K Thomopoulou, A Monastirioti, G Koronakis, MA Papadaki, ... Biomedicines 9 (4), 421, 2021 | 5 | 2021 |
| Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors D Makrakis, K Rounis, AP Tsigkas, A Georgiou, N Galanakis, G Tsakonas, ... Plos one 18 (2), e0277708, 2023 | 4 | 2023 |
| Circulating miRNAs as potential biomarkers in prostate cancer patients undergoing radiotherapy S Kachris, C Papadaki, K Rounis, E Tsitoura, C Kokkinaki, C Nikolaou, ... Cancer Management and Research, 8257-8271, 2021 | 4 | 2021 |
| High density of NRF2 expression in malignant cells is Associated with increased risk of CNS Metastasis in early-stage NSCLC G Tsakonas, A Martín-Bernabé, K Rounis, P Moreno-Ruiz, J Botling, ... Cancers 13 (13), 3151, 2021 | 2 | 2021 |
| Intergration of common clinical and laboratory parameters for predictive modeling of outcome with immune checkpoint inhibitors (ICIs) in patients (pts) with Nnon-small cell … K Rounis, D Makrakis, C Papadaki, AA Monastirioti, L Vamvakas, ... Journal of Clinical Oncology 38 (15_suppl), e21609-e21609, 2020 | 2 | 2020 |
| Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a … K Rounis, D Makrakis, C Papadaki, A Monastirioti, L Vamvakas, ... Plos one 18 (11), e0294382, 2023 | 1 | 2023 |
| Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies K Rounis, D Makrakis, I Gioulbasanis, S Ekman, L De Petris, D Mavroudis, ... Life 12 (6), 880, 2022 | 1 | 2022 |
